search
Back to results

Effectiveness of the Diaphragm for HIV Prevention

Primary Purpose

HIV Infection

Status
Withdrawn
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Ortho All-Flex diaphragm and Replens lubricant gel
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional prevention trial for HIV Infection focused on measuring Diaphragm, HIV prevention, Southern/South Africa, Zimbabwe, female-controlled methods, Replens, STI prevention, HIV Seronegativity

Eligibility Criteria

18 Years - 49 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Age 18 to 49 years old Sexually active (coital frequency at least four times per month on average) HIV negative based on testing within two weeks prior to enrollment Chlamydia trachomatis and Neisseria gonorrhoeae negative based on testing within 30 days prior to enrollment or if positive, completes treatment before enrollment Have a healthy cervix, as assessed by naked-eye speculum exam at enrollment Planning to live in the study area for the next 24 months Willing to be randomly assigned either to use or not use a latex diaphragm with lubricant gel during participation in the study, and to follow the protocol, including being tested for HIV and STIs Willing and able to give informed consent Exclusion Criteria: Known sensitivity or allergy to latex History of TSS (as suggested by current labeling for diaphragm use) Currently pregnant, or desiring to become pregnant in the next two years No cervix (total hysterectomy) Refuses treatment for diagnosed or suspected current STI and/or reproductive tract infection requiring treatment at enrollment Within six weeks of any pelvic surgery or last pregnancy outcome at the time of screening and enrollment Presence of clinically apparent lesion(s) with epithelial disruption at enrollment (may enroll after lesion(s) has healed, if otherwise eligible) Injected illicit drugs in the 12 months prior to screening and enrollment Blood transfusion or received blood products in 3 months prior to screening and enrollment Unable or unwilling to insert the diaphragm correctly Participation in any other clinical trial (including those of a vaginal product or barrier contraceptive). Verification by comparing participant lists to other concurrently running research studies may be conducted if necessary. Unable to speak English, Zulu, Shona, or Sotho Other conditions that, in the opinion of the investigator, would constitute contraindications to participation in the study or would compromise ability to comply with the study protocol, such as a major psychiatric disorder

Sites / Locations

  • Perinatal HIV Research Unit
  • Medical Research Council of South Africa
  • UZ-UCSF

Outcomes

Primary Outcome Measures

HIV incidence

Secondary Outcome Measures

STI incidence (CT, NG, syphilis, trichomoniasis, HSV2)
acceptability
feasibility and sustainability

Full Information

First Posted
July 12, 2005
Last Updated
March 3, 2015
Sponsor
University of California, San Francisco
Collaborators
Bill and Melinda Gates Foundation, Ibis Reproductive Health, Medical Research Council, South Africa, Women's Health Global Imperative, UZ-UCSF Collaborative Research Programme, Perinatal HIV Research Unit of the University of the Witswatersrand
search

1. Study Identification

Unique Protocol Identification Number
NCT00121459
Brief Title
Effectiveness of the Diaphragm for HIV Prevention
Official Title
The Latex Diaphragm to Prevent HIV Acquisition Among Women: A Female-Controlled, Physical Barrier of the Cervix
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Withdrawn
Why Stopped
PI left and no data or information is available.
Study Start Date
September 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
University of California, San Francisco
Collaborators
Bill and Melinda Gates Foundation, Ibis Reproductive Health, Medical Research Council, South Africa, Women's Health Global Imperative, UZ-UCSF Collaborative Research Programme, Perinatal HIV Research Unit of the University of the Witswatersrand

4. Oversight

5. Study Description

Brief Summary
The purpose of this trial is to determine whether using the diaphragm and a lubricant get can reduce women's risk of acquiring an HIV infection.
Detailed Description
This multi-site randomized, controlled trial will measure the effectiveness of the diaphragm in preventing heterosexual acquisition of HIV infection among women. This Phase III study is powered to detect effectiveness (biological efficacy combined with adherence) of 33 percent. Women in South Africa and Zimbabwe (N=4,500) at risk of contracting HIV will be invited to participate and will be followed for up to 24 months, with a total study duration of 4 years. All women will receive safer-sex counseling, free male condoms and diagnosis and treatment of sexually transmitted infections (STIs). Half of the participants will be randomly selected to receive an Ortho All-Flex latex diaphragm and Replens lubricant gel. We will assess whether women using diaphragms and lubricant gel have lower rates of HIV or STI infection than do their non-diaphragm and gel counterparts. Additionally, we will investigate the long-term acceptability of the diaphragm in this study population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infection
Keywords
Diaphragm, HIV prevention, Southern/South Africa, Zimbabwe, female-controlled methods, Replens, STI prevention, HIV Seronegativity

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
Ortho All-Flex diaphragm and Replens lubricant gel
Primary Outcome Measure Information:
Title
HIV incidence
Secondary Outcome Measure Information:
Title
STI incidence (CT, NG, syphilis, trichomoniasis, HSV2)
Title
acceptability
Title
feasibility and sustainability

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18 to 49 years old Sexually active (coital frequency at least four times per month on average) HIV negative based on testing within two weeks prior to enrollment Chlamydia trachomatis and Neisseria gonorrhoeae negative based on testing within 30 days prior to enrollment or if positive, completes treatment before enrollment Have a healthy cervix, as assessed by naked-eye speculum exam at enrollment Planning to live in the study area for the next 24 months Willing to be randomly assigned either to use or not use a latex diaphragm with lubricant gel during participation in the study, and to follow the protocol, including being tested for HIV and STIs Willing and able to give informed consent Exclusion Criteria: Known sensitivity or allergy to latex History of TSS (as suggested by current labeling for diaphragm use) Currently pregnant, or desiring to become pregnant in the next two years No cervix (total hysterectomy) Refuses treatment for diagnosed or suspected current STI and/or reproductive tract infection requiring treatment at enrollment Within six weeks of any pelvic surgery or last pregnancy outcome at the time of screening and enrollment Presence of clinically apparent lesion(s) with epithelial disruption at enrollment (may enroll after lesion(s) has healed, if otherwise eligible) Injected illicit drugs in the 12 months prior to screening and enrollment Blood transfusion or received blood products in 3 months prior to screening and enrollment Unable or unwilling to insert the diaphragm correctly Participation in any other clinical trial (including those of a vaginal product or barrier contraceptive). Verification by comparing participant lists to other concurrently running research studies may be conducted if necessary. Unable to speak English, Zulu, Shona, or Sotho Other conditions that, in the opinion of the investigator, would constitute contraindications to participation in the study or would compromise ability to comply with the study protocol, such as a major psychiatric disorder
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nancy Padian, PhD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
Perinatal HIV Research Unit
City
Soweto
State/Province
Gauteng
Country
South Africa
Facility Name
Medical Research Council of South Africa
City
Durban
State/Province
KwaZulu Natal
Country
South Africa
Facility Name
UZ-UCSF
City
Harare
Country
Zimbabwe

12. IPD Sharing Statement

Citations:
PubMed Identifier
29795625
Citation
Teasdale CA, Abrams EJ, Chiasson MA, Justman J, Blanchard K, Jones HE. Incidence of sexually transmitted infections during pregnancy. PLoS One. 2018 May 24;13(5):e0197696. doi: 10.1371/journal.pone.0197696. eCollection 2018.
Results Reference
derived
PubMed Identifier
26992693
Citation
Abbai NS, Wand H, Ramjee G. Biological factors that place women at risk for HIV: evidence from a large-scale clinical trial in Durban. BMC Womens Health. 2016 Mar 19;16:19. doi: 10.1186/s12905-016-0295-5.
Results Reference
derived
PubMed Identifier
25940115
Citation
Abbai NS, Wand H, Ramjee G. Socio-demographic and behavioural characteristics associated with HSV-2 sero-prevalence in high risk women in KwaZulu-Natal. BMC Res Notes. 2015 May 5;8:185. doi: 10.1186/s13104-015-1093-0.
Results Reference
derived
PubMed Identifier
25243015
Citation
Naidoo S, Wand H, Abbai NS, Ramjee G. High prevalence and incidence of sexually transmitted infections among women living in Kwazulu-Natal, South Africa. AIDS Res Ther. 2014 Sep 15;11:31. doi: 10.1186/1742-6405-11-31. eCollection 2014.
Results Reference
derived
PubMed Identifier
23934268
Citation
Ramjee G, Wand H. Geographical clustering of high risk sexual behaviors in "hot-spots" for HIV and sexually transmitted infections in Kwazulu-Natal, South Africa. AIDS Behav. 2014 Feb;18(2):317-22. doi: 10.1007/s10461-013-0578-x.
Results Reference
derived
PubMed Identifier
22223838
Citation
Wand H, Ramjee G. The relationship between age of coital debut and HIV seroprevalence among women in Durban, South Africa: a cohort study. BMJ Open. 2012 Jan 5;2(1):e000285. doi: 10.1136/bmjopen-2011-000285. Print 2012. Erratum In: BMJ Open. 2012 Sep 10;2(5):null.
Results Reference
derived
PubMed Identifier
21570554
Citation
Blanchard K, Bostrom A, Montgomery E, van der Straten A, Lince N, de Bruyn G, Grossman D, Chipato T, Ramjee G, Padian N. Contraception use and effectiveness among women in a trial of the diaphragm for HIV prevention. Contraception. 2011 Jun;83(6):556-63. doi: 10.1016/j.contraception.2010.10.018. Epub 2011 Jan 26.
Results Reference
derived
PubMed Identifier
21447515
Citation
de Bruyn G, Shiboski S, van der Straten A, Blanchard K, Chipato T, Ramjee G, Montgomery E, Padian N; MIRA Team. The effect of the vaginal diaphragm and lubricant gel on acquisition of HSV-2. Sex Transm Infect. 2011 Jun;87(4):301-5. doi: 10.1136/sti.2010.047142. Epub 2011 Mar 29.
Results Reference
derived
PubMed Identifier
20955629
Citation
van der Straten A, Cheng H, Minnis AM. Change in condom and other barrier method use during and after an HIV prevention trial in Zimbabwe. J Int AIDS Soc. 2010 Oct 19;13:39. doi: 10.1186/1758-2652-13-39.
Results Reference
derived
PubMed Identifier
18978097
Citation
Sawaya GF, Chirenje MZ, Magure MT, Tuveson JL, Ma Y, Shiboski SC, Da Costa MM, Palefsky JM, Moscicki AB, Mutasa RM, Chipato T, Smith-McCune KK. Effect of diaphragm and lubricant gel provision on human papillomavirus infection among women provided with condoms: a randomized controlled trial. Obstet Gynecol. 2008 Nov;112(5):990-7. doi: 10.1097/AOG.0b013e318189a8a4. Erratum In: Obstet Gynecol. 2010 Sep;116(3):775. Obstet Gynecol. 2016 Aug;128(2):411.
Results Reference
derived
PubMed Identifier
18941533
Citation
Ramjee G, van der Straten A, Chipato T, de Bruyn G, Blanchard K, Shiboski S, Cheng H, Montgomery E, Padian N; MIRA team. The diaphragm and lubricant gel for prevention of cervical sexually transmitted infections: results of a randomized controlled trial. PLoS One. 2008;3(10):e3488. doi: 10.1371/journal.pone.0003488. Epub 2008 Oct 22.
Results Reference
derived
PubMed Identifier
17631387
Citation
Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, Shiboski S, Montgomery ET, Fancher H, Cheng H, Rosenblum M, van der Laan M, Jewell N, McIntyre J; MIRA Team. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet. 2007 Jul 21;370(9583):251-261. doi: 10.1016/S0140-6736(07)60950-7.
Results Reference
derived
Links:
URL
http://www.ibisreproductivehealth.org
Description
Ibis Reproductive Health web site
URL
http://www.cervicalbarriers.org
Description
Cervical Barrier Advancement Society web site
URL
http://www.rti.org/wghi
Description
Women's Global Health Imperative
URL
http://www.uz-ucsf.co.zw/
Description
University of Zimbabwe, UCSF
URL
http://www.hivsa.com/
Description
Perinatal HIV Research Unit of South Africa

Learn more about this trial

Effectiveness of the Diaphragm for HIV Prevention

We'll reach out to this number within 24 hrs